Exagen Inc. reported financial results for the three and six months ended June 30, 2026. The company achieved record second-quarter revenue of $19.9 million, a 16% increase year-over-year, driven by an 11% growth in AVISE CTD test volume and a 4% rise in trailing-twelve-month average selling price to $446 per test. Net loss narrowed to $3.2 million from $4.4 million in the prior year quarter, while adjusted EBITDA improved significantly to a loss of $0.1 million compared to $1.7 million previously. The company raised its full-year 2026 revenue guidance to $72–$75 million from $70–$73 million and ended the period with approximately $24.6 million in cash. Exagen Inc. operates in the medical diagnostics industry, providing autoimmune testing solutions.

Exagen Inc. held its 2026 annual meeting of stockholders on June 9, 2026, where stockholders' final voting results are final. Tina S. Nova, Ph.D. and Scott Kahn, Ph.D. were elected as Class I directors for a three-year term. The stockholders' advisory vote on executive compensation was also conducted. Exagen Inc. operates in the biotechnology/healthcare/life sciences industry and develops products for immune system regulation.